SEC Tracker
Get the app

Agios Pharmaceuticals AGIO

Sarah Gheuens (AGIO) director JOHN DOE purchased 10,000 shares worth $500,000, signaling bullish insider sentiment and potential confidence in the company's future prospects.

Sarah Gheuens, insider filing for AGIO

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Agios Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
  2. Indivior Pharmaceuticals INDV public float $1.8B, Jun 30, 2025
  3. Bausch Health Companies BHC public float $2.0B, Jun 30, 2025
  4. Recursion Pharmaceuticals RXRX public float $2.0B, Jun 30, 2025
  5. Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.